News

BioMed SA eyes new road map to greater economic wins

BioMed SA President Ann Stevens (Photo by Lyndsey Johnson) By W. Scott Bailey, San Antonio Business ...

Military champion has Prytime Medical ready for prime time

Prytime Medical Devices Inc. CEO David Spencer said his company is poised to take its flagship technology ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
San Antonio biotech firm Bluegrass Vascular Technologies secures new leadership
September 2, 2014

Dr. Gabriele Niederauer has been named the new CEO of Bluegrass Vascular Technologies.

By W. Scott Bailey, San Antonio Business Journal

Bluegrass Vascular Technologies (BVT) has been quite busy of late by closing on a new round of funding and hiring a new chief executive to lead the biotech company.

In late July, I reported that the Kentucky-based medical technology company had closed on $4.5 million in new investor funding and was relocating to San Antonio. Now, BVT has secured a new leader who will help guide the next stages of the company's evolution.

BVT has named Dr. Gabriele Niederauer, a seasoned senior medical device executive, as its new president and CEO. Niederauer previously served as vice president of research and development for ArthoCare Corp.'s ENT-Sinus Division, where she was instrumental in developing and commercializing novel implants and instruments for sinus surgery. She has also held senior management roles with San Antonio-based ENTrigue Surgical, C2M Medical and the former OsteoBiologics. Smith & Nephew bought out OsteoBiologics in 2006 and later shuttered the company's San Antonio operations.

An experienced executive of early-stage companies, Niederauer has developed and launched dozens of products, including implants, instruments and fixation devices.

"Gabriele is a great addition to the team," says Dr. Paul Castella, senior managing partner for Targeted Technology Funds, a lead investor in BVT. "She has over 20 years of experience in the development and commercialization of medical devices and is a great fit to lead the company to commercialization in Europe and the U.S."

Following the recent closure of its Series A funding, BVT will focus its efforts on obtaining a CE Mark for its Surfacer Inside-Out Access Catheter System, a proprietary technology that allows physicians to gain venous access using a novel approach.

"BVT has developed a critical mission to address shortcomings in the venous access market," Niederauer explains. "I am honored to join the team and build upon that mission to bring superior, life-saving technologies to the market."

BVT co-founder and former CEO Jim Clifton will remain with the company and will transition into the chief operating officer position.

Stay informed. Subscribe to BioMed SA news alerts.